<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier		Not
name, catalogue number and RRID, if		Applicable

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information,		Not
strain. Provide accession number in		Applicable
repository OR supplier name, catalog		
number, clone number, OR RRID		
Primary cultures: Provide species, strain,		Not
sex of origin, genetic modification status.		Applicable

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex,		Not
age, genetic modification status. Provide		Applicable
accession number in repository OR supplier name,		
catalog number, clone number, OR RRID		
Animal observed in or captured from the		Not
field: Provide species, sex and age where		Applicable
possible		
Model organisms: Provide Accession		Not
number in repository (where relevant) OR		Applicable

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique		Not
accession number if available, and source		Applicable
(including location for collected wild specimens)		
Microbes: provide species and strain,		Not
unique accession number if available, and		Applicable

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or		Not
equivalent committee(s), provide reference number for approval.		Applicable
Provide statement confirming informed consent		Not
obtained from study participants.		Applicable
Report on age and sex for all study participants.		Not

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration	res (marcate where provided, section, paragraph)	Not
number OR cite DOI in manuscript.		Applicable
number on etc borni manuscript.		Applicable
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed		Not
step-by-step protocols are available.		Applicable
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been		
done, or if they were not carried out.		
Sample size determination		Not
Randomisation		Not
Blinding		Not
Inclusion/exclusion criteria		Not
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was		Not
replicated in laboratory		Applicable
Define whether data describe technical or		Not
biological replicates		Applicable
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State		Not
details of authority granting ethics approval (IRB		Applicable
or equivalent committee(s), provide reference		
number for approval.		
Studies involving experimental animals: State		Not
details of authority granting ethics approval (IRB		Applicable
or equivalent committee(s), provide reference		
number for approval.		
Studies involving specimen and field samples:	This was a bioinformatics study that utilized the	Not
State if relevant permits obtained, provide	public databases of TCGA and GEO, so no ethics	Applicable
details of authority approving study; if none	committee authorization was required.	
were required, explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of		Not
concern, state the authority granting approval		Applicable

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	Section Materials and methods/Paragraph 1	
excluded, and whether the criteria for exclusion		
were determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice	Section Materials and methods/Paragraph 6	
of tests.		i l

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are		Not
available, including protocols for access or		Applicable
restriction on access.		
If data are publicly available, provide accession	Section Materials and methods/Paragraph 1	
number in repository or DOI or URL.		
If publicly available data are reused, provide	Section Materials and methods/Paragraph 1	
accession number in repository or DOI or URL,		
where possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software		
essential for replicating the main findings of the		
State whether the code or software is available.		Not
		Applicable
If code is publicly available, provide accession	Section Materials and methods/Paragraph 1-6	
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

 $Article\ information:\ \underline{https://dx.doi.org/10.21037/jgo-22-1070}$